首页膀胱肿瘤治疗及预后证据详情

保留膀胱与根治性切除治疗肌层浸润性膀胱癌的 Meta 分析及初步探讨

原文: 2018 年 发布于 Support Care Cancer 36 卷 第 2 期 12-24 浏览量:226次 原文链接

作者: 李亚玮

作者单位: Department of Urology, Beijing Tiantan Hospital, Capital Medical University, No. 119 South 4th Ring West Road, Fengtai District, Beijing 100070, China. Department of Urology, Tengzhou Central People's Hospital, Tengzhou 277500, China. Department of Neurology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai 264000, Shandong, China.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.1371/journal.pone.0276453

关键词: T1期 非肌层浸润性膀胱癌 复发 进展 独立预后因素

文献简介

AIM: To determine which of the approved immune checkpoint inhibitors is the optimal treatment in metastatic urothelial bladder cancer. METHODS & MATERIALS: Only the pivotal Phase III trials of second-line metastatic urothelial bladder cancer were included in this network meta-analysis. RESULTS: This NMA included three pooled trials (NCT00315237, NCT02256436 and NCT02302807) of 1125 participants. Pembrolizumab was the only treatment with positive effect on overall survival compared with the best supportive care. The treatment discontinuation rates due to adverse events of the pembrolizumab and atezolizumab did not differ from that of the best supportive care. C onclusion: Our results confirmed the superiority of pembrolizumab in the management of metastatic urothelial bladder cancer.

热门文献